Skip to main content

What the science actually says about the medicine you are on.

Analysis of the GLP-1 literature to help you stay informed.

Side Effects

GLP-1 and Muscle Loss: Why It Happens and What Helps

Up to forty percent of the weight lost on a GLP-1 is lean mass, not fat. Why it happens, why it matters more after fifty, and what actually protects muscle.

2026-05-24Read
Side Effects

How Much Protein You Actually Need on a GLP-1

The standard 0.8 g/kg guideline was set for people who aren't in a deficit. On a GLP-1, the target to preserve muscle is meaningfully higher. Here are the numbers.

2026-05-24Read
Side Effects

Plant vs. Whey Protein for Preserving Muscle

Whey has the reputation, but a head-to-head trial found pea protein built muscle just as well, and for GLP-1 users plant protein has practical advantages too.

2026-05-24Read
New Molecules

The GLP-1 That Skips the Muscle

A third of the weight people lose on a GLP-1 is lean mass. The next generation of these drugs is being engineered around that number.

Issue 01 · 2026-05-20Read
The Frontier

The Cravings They Did Not Expect to Quiet

Alcohol. Nicotine. Gambling. The trials testing GLP-1s for addictions outside of food are no longer fringe. Here is what they actually show.

Issue 02 · 2026-05-20Read
Side Effects

Why the Brush Has More Hair Than the Floor

Hair shedding on a GLP-1 is real, common, and almost always brushed off as temporary. The biology is more specific than that, and so is what to do about it.

Issue 03 · 2026-05-20Read
New Molecules

How Much Weight, and Which Drug

The weight-loss numbers are not the same across these drugs. What each one delivered in its pivotal trial, charted, and why the differences matter less than the marketing.

Issue 04 · 2026-05-20Read
The Evidence

What the Heart Trial Actually Showed

The biggest thing semaglutide did in its largest trial had nothing to do with weight. It cut heart attacks and strokes in people who had never had diabetes.

Issue 05 · 2026-05-20Read
Side Effects

The Nausea Has a Shape

The most common reason people stop a GLP-1 is also the most predictable. It tracks the dose, peaks during the climb, and settles. Knowing the shape is most of managing it.

Issue 06 · 2026-05-20Read
Pillars

What we cover, and why.

Five beats. Every article belongs to one. Every claim has a citation.

I

Side effects

One piece per known side effect. The biology, the timeline, what the evidence supports.

II

The frontier

Non-obesity trials. Addiction. Alzheimer's. PCOS. Liver disease. Sleep apnea. CKD.

III

New molecules

Retatrutide. CagriSema. Survodutide. Amycretin. What the next generation does differently.

IV

The evidence

Landmark trials walked through in plain language. SURMOUNT. STEP. SELECT. ESSENCE.

V

Lived experience

Verified buyers, in their own words. Never invented. Always sourced.

Subscribe to the weekly.

One Tuesday email. One new piece, two notes from the past week in GLP-1 research, one practical thing you can do. No urgency mechanics, no countdown timers.

Unsubscribe any time. We never sell or share your address.